Evaluation of Intravenously Delivered Allogeneic Mesenchymal Stem Cells for Treatment of Elbow Osteoarthritis in Dogs: A Pilot Study

Abstract

Objectives The aim of this study was to evaluate the safety and collect pilot data measuring clinical effects of intravenously administered, adipose-derived, culture-expanded, allogeneic mesenchymal stem cells in dogs with elbow osteoarthritis. Materials and Methods Dogs (n = 13) with naturally occurring elbow osteoarthritis received three intravenous doses of allogeneic canine mesenchymal stem cells via an open-label clinical trial. Primary outcome measures collected over a 6-month study period included objective gait analysis, accelerometry, owner questionnaires and joint fluid analysis. Results No acute adverse events were observed following repeated intravenous treatment with allogeneic mesenchymal stem cells. A significant improvement in mean client-specific outcome measure (CSOM) activity score and CSOM behaviour score was observed when pre-treatment values were compared with post-treatment values (day >28). In contrast, mean peak vertical force significantly decreased from baseline to post-treatment (>day 28). Weekly activity counts did not show a significant difference between baseline to post-treatment time points. Synovial fluid biomarkers did not change during treatment, and labelled mesenchymal stem cells were rarely detected in synovial fluid samples collected after mesenchymal stem cell administration. Clinical Significance For dogs with naturally occurring elbow osteoarthritis, intravenous administration of mesenchymal stem cells was clinically well tolerated. While some subjective outcome measures showed significant improvements, objective outcome measures did not confirm similar changes. Further research is needed before intravenous mesenchymal stem cells can be recommended as a treatment for elbow osteoarthritis in dogs.

Evaluation of acupuncture for the treatment of pain associated with naturally-occurring osteoarthritis in dogs: a prospective, randomized, placebo-controlled, blinded clinical trial

“…CBPI questionnaires were conducted as described previously [ 32 ]. CSOM questions based on previously published information were divided into activity and behavior categories [ 41 ]. Owners were asked to pick five time and place specific questions related to activity and grade them on a 1–5 scale (1 = no problem, 2 = a little problematic, 3 = quite problematic, 4 = severely problematic, and 5 = impossible) and three questions related to behavior also graded on a 1–5 scale (1 = significantly less than normal, 2 = less than normal, 3 = normal amount, 4 = more than normal, and 5 = significantly more than normal).…”

In Vitro Cultures of Adipose-Derived Stem Cells: An Overview of Methods, Molecular Analyses, and Clinical Applications

“…Multiple studies have tried to evaluate the influence of ASC intra-articular injection and intravenous infusion on osteoarthritis treatment outcomes. It has been proven that the administration of ASCs could reduce pain and lameness, suppress the local inflammation, improve mobility and activity, and potentially promote cartilage regeneration [77][78][79][80][81].…”

“…Evaluation of intravenously delivered allogeneic mesenchymal stem cells for treatment of elbow osteoarthritis in dogs: A pilot study [77] Open-label clinical trial 13 dogs Elbow osteoarthritis Allogeneic Olsen,…”

Manufacturing and Banking Canine Adipose-Derived Mesenchymal Stem Cells for Veterinary Clinical Application

“…Meanwhile, there are no particularly effective treatments for these diseases, which not only affect the quality of life of the affected animals, but also require the owners to invest a lot of energy, time and money. Currently, many related reports have con rmed that AD-MSCs therapy in a variety of canine diseases in clinical trials have shown initial results [21][22][23][24][25].…”